
|Videos|September 24, 2021
Dr. Gao on treating re-emerged PARPi-resistant prostate cancer
Author(s)Urology Times staff
“Some potential…combination therapy may be valuable, such as combining with a checkpoint inhibitor or some target senescence because this resistance involves those kinds of mechanisms,” says Allen C. Gao, MD, PhD.
Advertisement
In this video, Allen C. Gao, MD, PhD, discusses the possibility of re-emerged PARP inhibitor resistant prostate cancer and what future studies should do to continue developing treatments. Gao was the senior author on the study, “
Gao is the Ralph de Vere White professor in the department of urologic surgery and director of urologic research at University of California, Davis.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
FDA approves lutetium Lu 177 vipivotide tetraxetan for PSMA-positive mHSPC
2
Testosterone deficiency: FAQs from the AUA guideline
3
Joshua Lang, MD, MS, on integrating molecular biomarkers into clinical practice
4
Large registry study reports durable 10-year outcomes with focal therapy for prostate cancer
5












